PMID- 29404296
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2278-330X (Print)
IS  - 2278-4306 (Electronic)
IS  - 2278-330X (Linking)
VI  - 6
IP  - 4
DP  - 2017 Oct-Dec
TI  - Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 
      non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as 
      the diagnostic modality in a significant subset.
PG  - 169-170
LID - 10.4103/sajc.sajc_65_17 [doi]
AB  - CONTEXT: Regional epidemiology of anaplastic lymphoma kinase (ALK) mutation in 
      non-small-cell lung cancer (NSCLC) is an unmet need in India, and so is the 
      knowledge of its incidence based on immunohistochemistry (IHC). AIMS: Reporting 
      the incidence of ALK mutation in NSCLC from Kolkata, incorporating IHC as the 
      diagnostic modality in a considerable subset of patients. SUBJECTS AND METHODS: 
      It is a retrospective observational study done on NSCLC patients with 
      adenocarcinoma histology, unselected by epidermal growth factor receptor, whose 
      samples were tested for ALK mutation status between March 1, 2013, and March 15, 
      2017. The study involved all cancer facilities in Kolkata, except Tata Medical 
      Centre. Up to June 2015, the tests were done by fluorescence in situ 
      hybridization (FISH) and from July 2015 to the end, tests were done using IHC, as 
      per the standard testing guidelines existing during the respective time periods. 
      Results were documented in a de-identified manner to analyze the incidence of ALK 
      mutations. RESULTS: A total of 379 patients was tested for ALK mutations. March 
      2013 to June 2015, 200 (52.77%) patients were tested by FISH, 17 (8.5%) samples 
      were unreportable and 4 patients [(2.19%) 4/183] tested positive for ALK 
      mutations. From July 2015 to March 2017, 179 (47.22%) patients were tested by 
      IHC, 9 (5.02%) samples were unreportable, and 10 patients [(5.88%) 10/170] tested 
      positive for ALK mutations. Overall, 26 (6.8%) samples were unreportable and 14 
      [(3.9%) 14/353] patients tested positive for ALK mutations. CONCLUSIONS: The 
      overall incidence of ALK mutation positive NSCLC in Kolkata is 3.9%. The 
      incidence by IHC is 5.88% and by FISH is 2.19%, in the subset of patients tested 
      by these two modalities respectively.
FAU - Chatterjee, Koushik
AU  - Chatterjee K
AD  - Department of Radiotherapy, IPGMER and SSKM Hospitals, Kolkata, West Bengal, 
      India.
FAU - Bhowmik, Raja
AU  - Bhowmik R
AD  - Department of Radiotherapy, IPGMER and SSKM Hospitals, Kolkata, West Bengal, 
      India.
FAU - Chattopadhyay, Bhargab
AU  - Chattopadhyay B
AD  - Department of Clinical Research, DACRRI, under CCRH, Ministry of AYUSH, Govt. of 
      India, Kolkata, West Bengal, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC5763628
OTO - NOTNLM
OT  - Anaplastic lymphoma kinase gene rearrangement
OT  - anaplastic lymphoma kinase mutation by immunohistochemistry
OT  - anaplastic lymphoma kinase mutation in lung adenocarcinoma unselected by 
      epidermal growth factor receptor
OT  - anaplastic lymphoma kinase mutation in nonsmall cell lung cancer
OT  - incidence of anaplastic lymphoma kinase mutation from Kolkata
COIS- There are no conflicts of interest.
EDAT- 2018/02/07 06:00
MHDA- 2018/02/07 06:01
PMCR- 2017/10/01
CRDT- 2018/02/07 06:00
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/02/07 06:01 [medline]
PHST- 2017/10/01 00:00 [pmc-release]
AID - SAJC-6-169 [pii]
AID - 10.4103/sajc.sajc_65_17 [doi]
PST - ppublish
SO  - South Asian J Cancer. 2017 Oct-Dec;6(4):169-170. doi: 10.4103/sajc.sajc_65_17.